Renvela generic
Renvela is an oral tablet prescribed by physicians and is owned by Sanofi. The active ingredient of Renvela is sevelamer carbonate. This drug was first authorized for market use on October 19, 2007.
When will Renvela generic be available?
The generic version of Renvela is expected to hit the market after October 27, 2025. This date marks the expiry of the last patent held by the company - patent number US7985418, titled 'Aliphatic amine polymer salts for tableting'. The release of a generic drug typically follows the expiration of the last patent of the original drug.
Renvela uses
Renvela, containing sevelamer carbonate, is used primarily to treat chronic kidney disease. The drug works by binding to phosphate molecules in foods consumed by the patient, helping to control serum phosphate levels in the body. Its efficiency in this purpose has led to its approval for use in the healthcare industry.
Renvela patent expiration
Renvela, the Sevelamer Carbonate tablet owned by Sanofi, has one patent registered. This patent (US7985418) is set to expire on October 27, 2025, which would mark the potential release date for Renvela generic. Below are the details of the patent: